SNAR-C3: A Drug Target / Disease Biomarker (G100170226)

Target Name: SNAR-C3

NCBI ID: G100170226

SNAR-C3

Other Name(s): Small NF90 (ILF3) associated RNA C3 | small NF90 (ILF3) associated RNA C3

SNAR-C3: A Drug Target / Disease Biomarker

SNAR-C3 is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and liver. It is a key regulator of cell death and has been linked to a number of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

One of the key functions of SNAR-C3 is its role in cell death, which is a critical process that helps remove damaged or dysfunctional cells from the body. When cells die, they can release a variety of molecules that can harm the body, including proteins, toxins, and metals. SNAR-C3 is involved in the process of programmed cell death, also known as apoptosis, which is the natural and necessary process by which cells are removed from the body.

In addition to its role in cell death, SNAR-C3 has also been shown to play a key role in the regulation of cellular signaling. It is a co-factor for several enzymes that are involved in cellular signaling pathways, including the production of reactive oxygen species (ROS) that can damage cells. ROS are a common cause of cellular damage and have been linked to a number of diseases, including neurodegenerative disorders and cancer.

The ability of SNAR-C3 to regulate cell death and cellular signaling has made it an attractive drug target for researchers. Many studies have shown that blocking the activity of SNAR-C3 can lead to a variety of beneficial effects, including the treatment of neurodegenerative disorders, cancer, and autoimmune diseases. In addition, the regulation of cell death and cellular signaling by SNAR-C3 is also thought to be involved in a variety of normal physiological processes, including the development and maintenance of tissues and organs.

SNAR-C3 is also of interest as a potential biomarker for a variety of diseases. The regulation of cell death and cellular signaling by SNAR-C3 is thought to be involved in the development and progression of many diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. For example, studies have shown that SNAR-C3 is expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder, and that blocking its activity may be a potential treatment for this disease. Similarly, the regulation of cell death and cellular signaling by SNAR-C3 has been linked to the development and progression of cancer, and blocking its activity may be a potential treatment for this disease.

In addition to its potential as a drug target and biomarker, SNAR-C3 is also of interest as a potential therapeutic approach for a variety of diseases. The regulation of cell death and cellular signaling by SNAR-C3 is thought to play a key role in the development and progression of many diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. By blocking its activity, it may be possible to treat these diseases and improve the quality of life for those affected.

Overall, SNAR-C3 is a protein that has significant interest as a drug target and biomarker for a variety of diseases. Its role in cell death and cellular signaling has made it an attractive target for researchers and therapeutic approaches, and its potential as a treatment for neurodegenerative disorders, cancer, and autoimmune diseases is a promising area of research. Further studies are needed to fully understand the role of SNAR-C3 in these diseases and to develop effective treatments.

Protein Name: Small NF90 (ILF3) Associated RNA C3

The "SNAR-C3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAR-C3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets